Literature DB >> 21959280

Antibacterial R&D incentives.

Ramanan Laxminarayan1, John H Powers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959280     DOI: 10.1038/nrd3560

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.

Authors:  Aaron S Kesselheim; Kevin Outterson
Journal:  Health Aff (Millwood)       Date:  2010-09       Impact factor: 6.301

2.  Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2007-09-01       Impact factor: 9.079

3.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

Authors: 
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

Review 4.  Impact of conjugate pneumococcal vaccines on antibiotic resistance.

Authors:  Ron Dagan; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2008-12       Impact factor: 25.071

  4 in total
  7 in total

1.  The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Authors:  Brad Spellberg; Priya Sharma; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

2.  Public funding of clinical-stage antibiotic development in the United States and European Union.

Authors:  Michael J Eichberg
Journal:  Health Secur       Date:  2015 May-Jun

Review 3.  Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics.

Authors:  Callum J Cooper; Mohammadali Khan Mirzaei; Anders S Nilsson
Journal:  Front Microbiol       Date:  2016-08-03       Impact factor: 5.640

4.  Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms.

Authors:  Marion J Skalweit; Mei Li
Journal:  Drug Des Devel Ther       Date:  2016-09-20       Impact factor: 4.162

Review 5.  In-vivo monitoring of infectious diseases in living animals using bioluminescence imaging.

Authors:  Pinar Avci; Mahdi Karimi; Magesh Sadasivam; Wanessa C Antunes-Melo; Elisa Carrasco; Michael R Hamblin
Journal:  Virulence       Date:  2017-12-08       Impact factor: 5.882

Review 6.  Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment.

Authors:  Amy Pruden; D G Joakim Larsson; Alejandro Amézquita; Peter Collignon; Kristian K Brandt; David W Graham; James M Lazorchak; Satoru Suzuki; Peter Silley; Jason R Snape; Edward Topp; Tong Zhang; Yong-Guan Zhu
Journal:  Environ Health Perspect       Date:  2013-06-04       Impact factor: 9.031

Review 7.  β-Lactam Antibiotics Renaissance.

Authors:  Wenling Qin; Mauro Panunzio; Stefano Biondi
Journal:  Antibiotics (Basel)       Date:  2014-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.